Navigation Links
Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
Date:10/22/2010

FRAZER, Pa., Oct. 22 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that Risk Evaluation and Mitigation Strategies (REMS) for its medications NUVIGIL® (armodafinil) Tablets [C-IV] and PROVIGIL® (modafinil) Tablets [C-IV] have been approved by the U.S. Food and Drug Administration (FDA).  Both the NUVIGIL and PROVIGIL REMS consist of a Medication Guide to inform patients about the potential risks associated with the use of these medications, a communication plan and a timetable for submission of assessments of the REMS.  The communication plan includes a Dear Healthcare Professional Letter, a Prescriber Brochure, a Pharmacist Action Letter and a dedicated REMS Internet Site. The introduction of the NUVIGIL and PROVIGIL REMS programs is consistent with the company's commitment to safe and appropriate use of its medications.

The goal of each REMS is to inform healthcare providers, patients and caregivers about the risks associated with these medications, including serious skin rash and hypersensitivity reactions.  The current product labeling for both medications contains a bolded warning that includes these risks. Neither medication is approved for use in the pediatric population for any indication.  In accordance with the approved REMS, the company is currently updating NUVIGIL and PROVIGIL labeling to include the Medication Guide.

The NUVIGIL and PROVIGIL Medication Guides will be available on each product website, www.nuvigil.com and www.provigil.com, and will be dispensed with every prescription.  Information on both products is also available by calling 1-800-896-5855.  More information on Cephalon and its products is available at www.cephalon.com.

About NUVIGIL NUVIGIL is ind
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and SAN DIEGO , Dec. 17, ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... solutions for cardiovascular applications, today announced that they have entered ... will commence a tender offer to acquire all of the ... share, or a total equity purchase price of USD 1 ...
(Date:12/17/2014)... NEW YORK , Dec. 17, 2014 /PRNewswire-USNewswire/ ... resonance imaging (MRI), the MRI market is seeing ... cardiovascular and breast MRI scans account for the ... providing a higher resolution of images, which are creating ... resonance imaging (MRI) market is growing at a ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... 2007 - Amgen,(NASDAQ:AMGN), today announced final ... which showed that Vectibix(TM) (panitumumab), a ... epidermal growth factor,receptor (EGFr), prolonged progression-free ... (BSC) in metastatic colorectal cancer,patients who ...
... Confirms and Extends Evidence Seen in a,Previous Study, ... Inc. today announced that investigators,at St. Jude Children's ... treatment in an animal model,of influenza using a ... strain that had caused fatal human infection in ...
Cached Medicine Technology:Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 2Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 3Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 4Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 5Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 6St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection 2St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection 3St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection 4St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection 5St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection 6
(Date:12/19/2014)... December 19, 2014 Diet Doc strives ... current approach to weight loss by combining ... The professionals at the company understand that remaining committed ... effects of eliminating carbohydrates and sugars from the diet ... to abandon their weight loss goals. , For ...
(Date:12/19/2014)... Novellus Healthcare Communications, LLC announces ... Clinics™, an independent journal that provides practical information ... for patients inside the pharmacy and retail clinics. ... optimal access to quality care, Inside Patient Care: ... team treating and coordinating patient care in pharmacies ...
(Date:12/19/2014)... Slone Partners , a ... healthcare information technology, and laboratory testing industries, has ... Operating Officer. The announcement comes after a year ... strengthened presence in Boston and several new additions ... breathes the client experience," said Adam Slone, Chief ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Being in good ... researchers report. They looked at data from more than ... who underwent treadmill tests between 1991 and 2009. Those ... chance of having high blood pressure at the start of ... with high levels of fitness. Of the more than ...
(Date:12/19/2014)... 2014 (HealthDay News) -- Traveling through the same U.S. ... to three others within a four-hour time span, illustrating ... report shows. "The exposures in this report were ... an international terminal, highlighting the fact that measles is ... an infectious disease specialist at the U.S. Centers for ...
Breaking Medicine News(10 mins):Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 3Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 4Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3
... Mich., April 21 /PRNewswire-FirstCall/ .- Perrigo Company,(Nasdaq: ... filed an Abbreviated New,Drug Application (ANDA) for over-the-counter ... a generic version of Monistat(R) 1,Combination Pack. The ... file an ANDA,with a Paragraph IV certification against ...
... CLEARWATER, Fla., April 21 Lincare Holdings,Inc. (Nasdaq: ... respiratory,therapy services delivered to patients in the home, today ... 2008., For the quarter ended March 31, 2008, ... $378.5 million for the first quarter of 2007.,The Company ...
... 21 In honor of their 25th,anniversary, Sierra Tucson ... April 30, 2008, from 8:30 -- 10:00 a.m. at ... S. Doheny Drive, Los,Angeles, CA 90048. Over 200 attendees ... their peers., Among those being recognized for their ...
... People with scalp or neck melanomas die at nearly ... body, including the face or ears, researchers at the University ... analysis of 51,704 melanoma cases in the U.S. confirms that ... Those with scalp or neck melanomas die at a rate ...
... enforcement agencies intensifying focus on hospital-physician ... ... /PRNewswire/ - The Deloitte Forensic Center reports,that complying with ... hospitals. Almost all physicians have ethical, mutually,beneficial relationships with ...
... West Nile Virus and Other Diseases, SACRAMENTO, Calif., ... hand. Coinciding with the launch of mosquito season, the,California ... April 25,2008 West Nile Virus and Mosquito and Vector ... mosquito-borne disease that can result in,debilitating cases of meningitis ...
Cached Medicine News:Health News:Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack 2Health News:Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack 3Health News:Lincare Holdings Inc. Announces First Quarter 2008 Financial Results 2Health News:Lincare Holdings Inc. Announces First Quarter 2008 Financial Results 3Health News:Lincare Holdings Inc. Announces First Quarter 2008 Financial Results 4Health News:Lincare Holdings Inc. Announces First Quarter 2008 Financial Results 5Health News:Most lethal melanomas are on scalp and neck 2Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 2Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 3Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 4Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 5Health News:State Legislature Declares April 21 to 25, 2008 West Nile Virus and Mosquito and Vector Control Awareness Week 2
Body Suit w/Bra torso...
Gynecomastia Vest...
Male Compression Vests...
Ideal for breast compression, adjustable hook and eye front closure with adjustable shoulder straps....
Medicine Products: